Unlocking the full potential of immunopeptidomics with the timsTOF Ultra

Overview

Alithea Biotechnology was founded in 2019 by Fanny Giannou and Tim Fugmann to support Biopharma globally on the development of innovative therapies targeting HLA-presented peptides. Alithea has a significant track record in the absolute quantification of HLA peptides, off-target toxicity predictions and target discovery. In addition, HLA-Compass is Alithea’s cloud-accessible HLA peptide database featuring the measurement of a total of 1.4 Million HLA peptides in 4160 healthy tissue, tumor tissue and cancer cell line samples for target validation and off-target toxicity prediction.

Why to join this webinar:

• The timsTOF Ultra can lead to high quality immunopeptidomes from limited sample
• Extensive HLA databases can significantly speed up the T-Cell-Receptor therapy development process
• The time is ripe to bring immunopeptidomics into clinical routine